Market Place
Sourcing Support
Lundbeck Appoints Chief AI Officer
19 Mar 2026 //
PHARMIWEB
Lundbeck Appoints Chief AI Officer
10 Mar 2026 //
PR NEWSWIRE
Lundbeck Presents Vyepti Data on Severe Migraine at HCOP
30 Jan 2026 //
PR NEWSWIRE BIO
After Avadel Setback, Lundbeck Signals Future M&A Rigor
22 Jan 2026 //
FIERCE PHARMA
Alkermes Response To Avadel Announcement
15 Nov 2025 //
PR NEWSWIRE
Avadel Receives Unsolicited Proposal From Lundbeck
14 Nov 2025 //
GLOBENEWSWIRE
Lundbeck, Otsuka Back Survey On Alzheimer`s Agitation
12 Nov 2025 //
FIERCE PHARMA
Lundbeck Reports 14% Revenue Growth Fueled By Vyepti
11 Nov 2025 //
PR NEWSWIRE
Lundbeck & Openai Join Forces to Innovation & Boost Productivity
27 Oct 2025 //
PHARMIWEB
Lundbeck Partner With Migraine Community To Enhance Migraine Care
25 Sep 2025 //
BUSINESSWIRE
Otsuka, Lundbeck`s Rexulti snubbed by FDA in PTSD
22 Sep 2025 //
FIERCE PHARMA
Lundbeck Exits 27 Markets, Lays Off 602 Staff
09 Sep 2025 //
FIERCE PHARMA
Lundbeck Optimistic on Rexulti PTSD Use Despite Adcomm Vote
15 Aug 2025 //
FIERCE PHARMA
Lundbeck Advances Migraine Leadership at AHS 67th Annual Meeting
19 Jun 2025 //
BUSINESSWIRE
Lundbeck partners Danish AI Centre to enhance drug discovery
06 May 2025 //
PR NEWSWIRE
Lundbeck to present pipeline data at AAN Annual Meeting
04 Apr 2025 //
PR NEWSWIRE
Lundbeck ends subcutaneous migraine cohort after futility review
01 Apr 2025 //
FIERCE BIOTECH
Lundbeck expands finding to IV Lu AG09222 in migraine prevention
31 Mar 2025 //
PR NEWSWIRE
Lundbeck`s Annual General Meeting held on 26 March 2025
26 Mar 2025 //
PR NEWSWIRE
Rxulti® approved in EU for treating schizophrenia in adolescents
13 Mar 2025 //
PR NEWSWIRE
FDA Grants Fast Track To Lundbeck’s Amlenetug For System Atrophy
12 Feb 2025 //
PR NEWSWIRE
Lundbeck`s Multiple System Atrophy Drug Gets Fast Track Nod
11 Feb 2025 //
CONTRACTPHARMA
Lundbeck Reports Positive 12-Month OLE Results For Bexicaserin
30 Jan 2025 //
PR NEWSWIRE
JAMA Psychiatry Publishes Otsuka, Lundbeck PTSD Trial Results
18 Dec 2024 //
BUSINESSWIRE
Lundbeck Showcases Commitment to Rare Epilepsy at AES Meeting
05 Dec 2024 //
PR NEWSWIRE
Lundbeck acquires all outstanding shares of Longboard Pharma
04 Dec 2024 //
PRESS RELEASE
Lundbeck Initiates Phase III Trial with Amlenetug for MSA
27 Nov 2024 //
PHARMAWEB
Lundbeck slashes value of $250M Abide buyout after pain setback
24 Oct 2024 //
FIERCE BIOTECH
Denmark`s Lundbeck bets on epilepsy drug with $2.6 bln Longboard deal
15 Oct 2024 //
REUTERS
Barbara Corcoran Raises Awareness For Alzheimer`s
26 Sep 2024 //
BUSINESSWIRE
Lundbeck Leaves US Trintellix To Takeda, Focuses On Rexulti
01 Aug 2024 //
FIERCE PHARMA
Otsuka And Lundbeck Present REXULTI® Data At AAIC 2024
31 Jul 2024 //
BUSINESSWIRE
Lundbeck To Present Migraine, Cluster Headache Data At American Headache Society
13 Jun 2024 //
BUSINESSWIRE
Otsuka, Lundbeck start ad push for long-acting bipolar drug
05 Jun 2024 //
FIERCE PHARMA
Rexulti the surprise winner in April`s TV drug ad spending list
07 May 2024 //
FIERCE PHARMA
Otsuka, Lundbeck sNDA for Brexpiprazole+Sertraline in PTSD
09 Apr 2024 //
PRESS RELEASE
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI
18 Mar 2024 //
BUSINESSWIRE
Lundbeck`s new CEO van Zyl talks long-term growth plan
23 Jan 2024 //
FIERCE PHARMA
Lundbeck encourages migraine patients to ‘Say Yep’ to its IV-infused med
19 Jan 2024 //
ENDPTS
Lundbeck, Otsuka dial down the drama for Rexulti agitation ad
13 Oct 2023 //
FIERCE PHARMA
AbbVie, Lundbeck ask FDA to revise draft guidance on migraine drugs
01 Aug 2023 //
ENDPTS
Otsuka, Lundbeck`s campaign spotlights agitation symptoms in Alzheimer’s disease
26 Jul 2023 //
ENDPTS
Lundbeck hires UCB neurology exec as new CEO
27 Jun 2023 //
FIERCE PHARMA
Otsuka & Lundbeck Announce US FDA Approval of (sNDA) for REXULTI®
10 May 2023 //
BUSINESSWIRE
Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Devp KCNQ2 Lundbeck
08 May 2023 //
BIOSPACE
FDA Approves First Bi-Monthly Injectable for Schizophrenia, Bipolar 1
02 May 2023 //
CONTRACT PHARMA
FDA Greenlights First Bi-Monthly Inje for Schizophrenia, Bipolar 1 Disorder
02 May 2023 //
BIOSPACE
FDA signs off on Otsuka and Lundbeck`s longer-acting Abilify
29 Apr 2023 //
FIERCE PHARMA
Otsuka, Lundbeck head into FDA panel with agency support
13 Apr 2023 //
FIERCE PHARMA
FDA backs Rexulti for first approval for agitation associated with Alzheimer’s dementia
12 Apr 2023 //
ENDPTS
Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month
04 Apr 2023 //
BUSINESSWIRE
Otsuka, Lundbeck eye Alzheimer`s indication in FDA adcomm
29 Mar 2023 //
ENDPTS
Takeda and Lundbeck change tactics on Trintellix depression campaign
23 Mar 2023 //
ENDPTS
Otsuka and Lundbeck Announce FDA Acceptance of sNDA for Brexpiprazole
07 Jan 2023 //
BUSINESSWIRE
Otsuka & Lundbeck Present Positive Data From Phase 3 Studies for Brexpiprazole
01 Dec 2022 //
BUSINESSWIRE
Lundbeck-partnered preclinical biotech nabs Series A from AstraZeneca
29 Nov 2022 //
ENDPTS
In new deal, AstraZeneca places small bet on `critical but challenging` target
28 Nov 2022 //
ENDPTS
Otsuka And Lundbeck Generate Exploratory Data In Major Depressive Disorder
03 Oct 2022 //
NEWSWISE
FDA accepts Otsuka filing for long-acting schizophrenia drug
14 Sep 2022 //
FIERCEPHARMA
